These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1977430)

  • 21. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.
    Molajo AO; Bennett DH; Marlow HF; Snow HM; Bastain W
    Br J Clin Pharmacol; 1987 Sep; 24(3):373-9. PubMed ID: 2889460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study.
    Koh KK; Song JH; Kwon KS; Park HB; Baik SH; Park YS; In HH; Moon TH; Park GS; Cho SK
    Int J Cardiol; 1995 Nov; 52(2):167-74. PubMed ID: 8749878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
    Vigholt-Sørensen E; Faergeman O; Snow HM
    Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
    Kochiadakis GE; Kanoupakis EM; Kalebubas MD; Igoumenidis NE; Vardakis KE; Mavrakis HE; Vardas PE
    Europace; 2001 Jan; 3(1):73-9. PubMed ID: 11271956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity.
    Channer KS; James MA; MacConnell T; Rees JR
    Br J Clin Pharmacol; 1994 Jan; 37(1):53-7. PubMed ID: 7908532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xamoterol versus digoxin in heart failure.
    Lancet; 1988 Apr; 1(8590):877. PubMed ID: 2895376
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness of diltiazem in controlling ventricular response and improving exercise capacity in chronic atrial fibrillation. Double-blind, cross-over study].
    Vitale P; Auricchio A; De Stefano R; Agretto A; De Simone R; Vitale N; Barbato F; Iacono A
    Cardiologia; 1989 Jan; 34(1):73-81. PubMed ID: 2720716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation.
    Zoble RG; Brewington J; Olukotun AY; Gore R
    Am J Cardiol; 1987 Aug; 60(6):39D-45D. PubMed ID: 3307366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of labetalol in chronic atrial fibrillation.
    Wong CK; Lau CP; Leung WH; Cheng CH
    Am J Cardiol; 1990 Nov; 66(17):1212-5. PubMed ID: 2239725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of oral amiodarone in controlling heart rate in patients with persistent atrial fibrillation who have undergone digitalisation.
    Kochiadakis GE; Kanoupakis EM; Igoumenidis NE; Mavrakis HE; Kafarakis PK; Vardas PE
    Hellenic J Cardiol; 2005; 46(5):336-40. PubMed ID: 16295942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation.
    Lewis RV; McDevitt DG
    Br J Clin Pharmacol; 1988 May; 25(5):603-6. PubMed ID: 3044426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Furlong R; Brogden RN
    Drugs; 1988 Oct; 36(4):455-74. PubMed ID: 2906865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xamoterol in hypertrophic cardiomyopathy: effects on diastolic function and heart rate.
    Gilligan DM; Stewart R; Chan WL; Oakley CM
    Int J Cardiol; 1992 Jun; 35(3):377-86. PubMed ID: 1351887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.
    Sørensen EV; Faergeman O; Day MA; Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):86S-88S. PubMed ID: 2572265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation.
    Tse HF; Lam YM; Lau CP; Cheung BM; Kumana CR
    Clin Exp Pharmacol Physiol; 2001; 28(5-6):446-50. PubMed ID: 11380520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.